Using this model in a genetic screen, we identified 24 promising hits that, when silenced in the hemocytes, attenuated the leukemia phenotype of the KRASG12V model, including two key components of the hypoxia pathway, HIF1A and ARNT (HIF1B), which are involved in the development of both solid tumors and hematological malignancies (Deynoux et al., 2016; Jun et al., 2017; Semenza, 2003; Szymczak et al., 2018). The gene discussed is HIF1A; the disease is leukemia.